Fibrocell Science Inc (FCSC)
(Delayed Data from NSDQ)
$2.24 USD
+0.02 (0.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.24 USD
+0.02 (0.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
by Zacks Equity Research
Key highlights of the past week are collaborations and pipeline updates.
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
by Zacks Equity Research
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
by Zacks Equity Research
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.
Intrexon Reports Preliminary Earnings and Revenues for Q2
by Zacks Equity Research
Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.
4 Best Performing Biotech Stocks of June: More Room to Run?
by Indrajit Bandyopadhyay
Biotech industry experiences a turnaround in June. Here are four stocks riding the rally.
Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Fibrocell Science, Inc. (FCSC) has been struggling lately, but the selling pressure may be coming to an end soon
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Intrexon's (XON) loss in the fourth quarter of 2017 was narrower than expected.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investor focus are likely to remain on Intrexon's (XON) performance along with other developmental updates during the quarterly call.
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.
Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?
by Zacks Equity Research
Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.
Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?
by Zacks Equity Research
Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Intrexon (XON) reported narrower-than-expected loss but revenues missed estimates in the third quarter of 2017. The company remains focused on the development of its pipeline candidates.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.
Implied Volatility Surging for Fibrocell Science (FCSC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fibrocell Science (FCSC) stock based on the movements in the options market lately.
What's in Store for Intrexon (XON) in this Earnings Season?
by Zacks Equity Research
Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.
Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9%
by Zacks Equity Research
Fibrocell Science, Inc. (FCSC) moved big last session, as its shares rose almost 14% on the day.
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Intrexon Corporation (XON) reported loss per share of 26 cents in the first quarter of 2017, which was wider than the Zacks Consensus Estimate loss of 23 cents.
Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.
Intrexon (XON) Q4 Loss Wider than Expected, Revenues Lag
by Zacks Equity Research
Intrexon reported adjusted loss per share of 26 cents in the fourth quarter of 2016 wider than the Zacks Consensus Estimate loss of 23 cents.
New Strong Buy Stocks for June 30th
by Swarup Gupta
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday